ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Clinical trials for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) explained in plain language.
Never miss a new study
Get alerted when new ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY) trials appear
Sign up with your email to follow new studies for ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
10-Year study tracks heart drug vyndamax in Real-World patients
Disease control OngoingThis study is monitoring 110 adults in Korea who are taking Vyndamax (tafamidis) for a rare heart condition called ATTR-CM. The goal is to track side effects and see how well the drug works over 10 years in everyday medical practice. Researchers will check heart function and symp…
Matched conditions: ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
German health data reveals how rare heart condition affects patients
Knowledge-focused OngoingThis study uses anonymous health insurance records from Germany to learn more about a rare heart condition called ATTR-CM, where abnormal protein builds up in the heart. Researchers will look at survival rates, hospital visits, and how common the disease is. No new treatments are…
Matched conditions: ATTR-CM (TRANSTHYRETIN AMYLOID CARDIOMYOPATHY)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC